Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
20
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Medicenna Therapeutics Corp market cap is $9.53M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Medicenna Therapeutics Corp 52 week high is $1.30 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Medicenna Therapeutics Corp 52 week low is $0.11 as of November 22, 2026.
Medicenna Therapeutics Corp stock price today is $0.1228.
Medicenna Therapeutics Corp stock price yesterday was $0.14.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Medicenna Therapeutics Corp's P/E ratio is -0.83.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Medicenna Therapeutics Corp P/B ratio is -7.543.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Medicenna Therapeutics Corp 50-day moving average is $0.2831.